Department of Medical Oncology.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Curr Opin Oncol. 2020 Sep;32(5):451-458. doi: 10.1097/CCO.0000000000000659.
The randomized OVHIPEC study provided further evidence that adding heated intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery significantly improved recurrence-free and overall survival in stage III epithelial ovarian cancer (EOC) patients, who were ineligible for primary cytoreductive surgery due to extensive intraperitoneal disease. Because opinions have been divided as to whether HIPEC is now a new standard of care for advanced EOC, the pros and cons of this approach are examined. A comparison with the ongoing discussion about the role of intraperitoneal chemotherapy is made.
For both techniques, experience is crucial and a learning curve essential. Compared with intraperitoneal chemotherapy, intraoperative application of HIPEC provides superior distribution through the peritoneal cavity. HIPEC, as given in OVHIPEC, did not significantly increase adverse events, had no negative effect on quality of life and was cost-effective.
Despite the ongoing debate about HIPEC, an important first step in attempting to demonstrate the efficacy of HIPEC in the first-line setting has been made with OVHIPEC. Critics have been of value to optimize future trials with HIPEC in patients with EOC.
OVHIPEC 随机研究进一步证明，在因广泛腹腔疾病而不能进行初始减瘤手术的 III 期上皮性卵巢癌（EOC）患者中，添加腹腔内热化疗（HIPEC）可显著提高无复发生存率和总生存率。由于 HIPEC 是否现在是高级 EOC 的新标准存在分歧，因此对这种方法的优缺点进行了检查。还与正在讨论的关于腹腔内化疗作用的问题进行了比较。
对于这两种技术，经验至关重要，学习曲线必不可少。与腹腔内化疗相比，术中应用 HIPEC 可更有效地在腹腔内分布。OVHIPEC 中的 HIPEC 并未明显增加不良事件，对生活质量没有负面影响，并且具有成本效益。
尽管对 HIPEC 仍存在争议，但 OVHIPEC 为在一线治疗中尝试证明 HIPEC 的疗效迈出了重要的第一步。批评者对于优化未来在 EOC 患者中进行的 HIPEC 试验很有价值。
